2017 Meeting Archives

Click here to view the End TB 2017 Abstract Book.

Presentation Slides - February 22, 2017

The Impact of Laboratory Advances on Clinical and Public Health Practice

Whole Genome Sequencing for the Diagnosis of Drug Resistance: are we there yet?
Dr. Maha Farhat, Harvard University, Boston, MA, USA

Understanding Transmission in Low-Incidence Settings with Whole Genome Sequencing
Dr. Jennifer Gardy, BC Centre for Disease Control, Vancouver, BC, Canada

WHO/ATS TB Treatment Guidelines

TB Laboratory Diagnostics LPA FLD/SLD (video-conference)
Dr. Christopher Gilpin, World Health Organization, Geneva, Switzerland

ATS/CDC/IDSA Treatment of TB Guidelines
Dr. Payam Nahid, University of California San Francisco, San Francisco, CA, USA

Ethics: Ethical Issues in the Implementation of the WHO's End TB Strategy
Dr. Diego Silva, Simon Fraser University, Burnaby, BC, Canada

Presentation Slides - February 23, 2017

Stop TB Meeting: Global and Regional Challenges in TB Elimination

Global Impact of the Short-Course TB Regimen
Dr. Charles Daley, National Jewish Health, Denver, CO, USA

Advocacy for Drug Access
Mr. Suraj Madoori, Treatment Action Group, New York, NY, USA

The 3P Project: Accelerating Innovation and Access to TB Medications
Dr. Grania Brigden, The Union, Paris, France

Nursing-Sponsored Session: TB Elimination through Collaborative Partnerships

Cultural Proficiency - Fundamental Concepts
Ms. Kay Wallis, Curry International Tuberculosis Center, Oakland, CA, USA

Orientation to SNTC Country Specific Guides for Health Professionals Working with Foreign-born Clients
Dr. Connie Haley, Southeastern National Tuberculosis Center, Gainesville, FL, USA

New Technologies and TB – TB ECHO Projects
Ms. Diana Fortune, New Mexico Department of Health, Santa Fe, New Mexico, USA

The George Comstock Lecture

Putting Quality on the Tuberculosis Agenda
Dr. Madhukar Pai, McGill University, Montreal, QC, Canada

Presentation Slides - February 24, 2017

TB in Remote Northern and Indigenous Communities

TB in the Global North - Caring for Those in Remote and Indigenous Communities
Dr. Lisa V. Adams, Dartmouth College, Hanover, NH, USA

Social Determinants of Health in Remote Communities
Dr. Malcolm King, Simon Fraser University, Burnaby, BC

Virtual Clinic Models for Managing Remote Care
Dr. Richard Long, University of Alberta, Edmonton, AB, Canada

Implementation of GeneXpert Testing in Remote Communities: From A to Z
Dr. Gonzalo Alvarez, University of Ottawa, Ottawa, ON, Canada

TB Immigration and Migration

Role of Expanded LTBI Testing and Treatment in TB Elimination Efforts
Dr. Philip LoBue, Centers for Disease Control and Prevention, Atlanta, GA, USA

Presentation Slides - February 25, 2017

TB and New Technologies

The WHO Digital Health Agenda for the End TB Strategy
Dr. Dennis Falzon, World Health Organization, Geneva, Switzerland

VDOT in the UK: Results of a Randomized Control Trial
Dr. Alistair Story, University College London, London, UK

Use of PCR-based Diagnostics in the United States
Dr. Neha Shah, Centers for Disease Control and Prevention, Richmond, CA, USA

Subclinical TB: Immunology and Host Response

Developing an RNA Signature Predictive of TB Progression
Dr. Dan Zak, Center for Infectious Disease Research, Seattle, WA, USA

What is Persistence?
Dr. David Sherman, Center for Infectious Disease Research, Seattle, WA, USA


Read the 2017 NAR Disclosure and Accreditation Statement

Read the 2017 NAR Conference List of Objectives

Page Last Updated: 21/04/2017